### Scientific program

#### Sunday 21 August 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 18:00</td>
<td><strong>Registration desk</strong> (Boulevard foyer) &lt;br&gt; <strong>Conference sessions</strong> (Boulevard Auditorium)</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td><strong>WELCOME TO COUNTRY</strong>  &lt;br&gt; <strong>CONFERENCE OPENING</strong>  &lt;br&gt; France Mentré, Chair of the WCoP Executive Committee &lt;br&gt; <strong>WELCOME TO DELEGATES</strong>  &lt;br&gt; Stefanie Hennig, Chair WCoP Local Organizing Committee</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td><strong>KEYNOTE PRESENTATION</strong>  &lt;br&gt; Chair: Stefanie Hennig  &lt;br&gt; The big world challenges for pharmacometrics - #100 Prof Mats Karlsson, Uppsala University, Sweden</td>
</tr>
<tr>
<td>17:00 – 18:00</td>
<td><strong>WELCOME RECEPTION</strong> (Boulevard foyer)</td>
</tr>
</tbody>
</table>

#### Monday 22 August 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td><strong>Poster Viewing</strong> (Boulevard foyer)</td>
</tr>
<tr>
<td>09:00 – 10:00</td>
<td><strong>KEYNOTE PRESENTATION</strong>  &lt;br&gt; Chair: Carl Kirkpatrick  &lt;br&gt; Challenges in treating infectious disease - linking epidemiology with pharmacometrics - #101 Dr Steve Kern, Global Health – Integrated Development, USA</td>
</tr>
<tr>
<td>10:00 – 10:25</td>
<td><strong>Morning tea</strong> (Boulevard foyer)</td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td><strong>SYMPOSIUM 1</strong>  &lt;br&gt; The optimal design, analysis, and translation of infectious disease human challenge models (Facilitated by Carl Kirkpatrick and Craig Rayner)  &lt;br&gt; <strong>Opening remarks</strong>  &lt;br&gt; <strong>Developing next-generation malaria medicines to address drug resistance and increase the operational feasibility of malaria elimination efforts - #102 David Reddy, Medicines for Malaria Venture, Switzerland</strong>  &lt;br&gt; <strong>Pharmacometric modelling of antimalarial drugs in development: from challenge to clinics - #103 Nathalie Gobeau, Medicines for Malaria Venture, Switzerland</strong>  &lt;br&gt; <strong>Introduction to human challenge models for respiratory viruses and the application of quantitative pharmacology to enhance drug development - #105 Craig Rayner, d3 Medicine LLC and Monash University, Australia</strong>  &lt;br&gt; <strong>Pharmacometric modelling of antimalarial drugs in development - #104 Joel Tarning, Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand</strong>  &lt;br&gt; <strong>Challenges and pitfalls of building models for Flu/RSV and respiratory viruses - #106 Kashyap Patel, Monash-d3 medicine, Australia</strong>  &lt;br&gt; <strong>A population model for respiratory syncytial virus (RSV) kinetics using transit compartments based on human challenge data - #107 Julia Korell, Model Answers, Australia</strong>  &lt;br&gt; <strong>Lunch</strong> (Boulevard foyer)  &lt;br&gt; <strong>POSTER PRESENTATIONS (12:15 – 13:15)</strong> &lt;br&gt; 1. The optimal design, analysis, and translation of infectious disease human challenge models 2. Hospital-based pharmacometrics 3. Language, libraries and connectors 9. Other (abstracts #221 – #226)</td>
</tr>
<tr>
<td>13:30 – 15:00</td>
<td><strong>SYMPOSIUM 2</strong>  &lt;br&gt; Hospital-based pharmacometrics (Facilitated by Kyungsoo Park and Yusuke Tanigawara)  &lt;br&gt; <strong>Opening remarks</strong>  &lt;br&gt; <strong>Evaluation of linezolid-induced thrombocytopenia based on hospital pharmacometrics - #108 Yasuhiro Tsuji, University of Toyama, Japan</strong>  &lt;br&gt; <strong>NextDose: a web-based collaborative tool for target concentration intervention - #109 Sam Holford, University of Auckland, New Zealand</strong>  &lt;br&gt; <strong>Modeling tumor size and survival in patients with metastatic gastric cancer - #110 Dong Woo Chae, Yonsei University, Korea</strong>  &lt;br&gt; <strong>Road to individualising tacrolimus therapy in solid organ transplant recipients - #111 Christine Staatz, The University of Queensland, Australia</strong>  &lt;br&gt; <strong>Understanding the influence of vitamin K on warfarin dosing requirements - #112 Qing-Xi Ooi, University of Otago, New Zealand</strong>  &lt;br&gt; <strong>Afternoon tea</strong> (Boulevard foyer)</td>
</tr>
<tr>
<td>15:00 – 15:25</td>
<td><strong>SYMPOSIUM 3</strong>  &lt;br&gt; Language, libraries and connectors (Facilitated by Mats Karlsson and Nick Holford)  &lt;br&gt; <strong>Opening remarks</strong>  &lt;br&gt; <strong>How can users benefit from the DDMoRe common language standard and interoperability framework? - #113 Phylinda Chan, Pfizer, United Kingdom</strong>  &lt;br&gt; <strong>What purpose is the DDMoRe library serving? - #114 Inaki Troconiz, University of Navarra, Spain</strong>  &lt;br&gt; <strong>Would a certification process for models published on the DDMoRe repository serve the modelling community? - #115 Siv Jönsson, Uppsala University, Sweden</strong>  &lt;br&gt; <strong>What advanced methods and algorithms are promoted through DDMoRe? – #116 Andrew Hooker, Uppsala University, Sweden</strong>  &lt;br&gt; <strong>Evening at leisure</strong></td>
</tr>
</tbody>
</table>
08:30 – 17:00 Registration desk (Boulevard foyer) Conference sessions (Boulevard Auditorium)

08:30 – 09:00 POSTER VIEWING (Boulevard foyer)

09:00 – 10:00 KEYNOTE PRESENTATION
Chair: Lena Friberg

Why MIC is poison for the mind - #117 Prof Hartmut Derandorf, University of Florida, USA

10:20 – 10:25 Morning tea (Boulevard foyer)

10:30 – 12:00 SYMPOSIUM 4
Bridging the gap between pharmacometricians and statisticians (Facilitated by France Mentré)

10:30 – 10:35 Opening remarks

10:35 – 10:55 Pharmacometricians and statisticians in drug development: can’t we all just get along? - #118 Stacey Tannenbaum, Astellas, USA

10:55 – 11:25 When statistics and pharmacometrics join forces for advanced quantitative drug development: A case study - #119 Emmanuel Zuber, Novartis Pharma, Switzerland

11:25 – 11:45 Regulatory-endorsed M&S platforms: The case of Alzheimer Disease CTS - #120 Klaus Romero, Critical Path Institute, USA

11:45 – 12:00 Pharmacometrics, biostatistics and computational biology postgraduate training: How can we integrate courses? - #121 Julie Simpson, The University of Melbourne, Australia

12:00 – 13:25 Lunch (Boulevard foyer)

POSTER PRESENTATIONS (12:15 – 13:15)
1. Bridging the gap between pharmacometricians and statisticians
2. Pharmacometric approaches to optimize dose selection
3. Application of models for solid tumor dynamics to oncology drug development
4. Other (abstracts #248 – #253)

13:30 – 15:00 SYMPOSIUM 5
Pharmacometric approaches to optimize dose selection (Facilitated by Stacey Tannenbaum)

13:30 – 13:35 Opening remarks

13:35 – 13:55 Recap of the EMA/EFPIA workshop on dose finding - #122 Flora Musumbu Tshihanu, University College London, United Kingdom


14:10 – 14:35 Leaping from plasma and saliva PK to optimize dose selection for optimal drug use - #124 Catherine Sherwin, University of Utah, USA

14:35 – 15:00 Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder - #125 Mats Magnusson, Pharmatheus, Sweden

15:00 – 15:25 Afternoon tea (Boulevard foyer)

15:30 – 17:00 SYMPOSIUM 6
Application of models for solid tumor dynamics to oncology drug development (Facilitated by Holly Kimko)

15:30 – 15:55 Modeling and simulation with evolving cancer therapies: Combinations, cancer immunotherapy, and more - #126 Jin Yan Jin, Genentech Inc, USA

15:55 – 16:20 Bench-to-bedside translation of antibody drug conjugates (ADCs) using a multiscale mechanistic PK/PD model - #127 Dhaval K Shah, The State University of New York at Buffalo, USA

16:20 – 16:35 Optimization of trial design and dose selection based on the quantitative assessment of the efficacy of TAK-385, an investigational, oral GnRH antagonist, in patients with prostate cancer - #128 Nelleke Snelder, LAP&P Consultants BV, Netherlands

16:35 – 17:00 An analysis of patient-reported outcomes (PRO) in breast cancer patients through item-response theory (IRT) pharmacometric modeling - #129 Emilie Schindler, Uppsala University, Sweden

19:00 – 23:00 CONFERENCE DINNER (Sky Room, Sky level, Brisbane Convention & Exhibition Centre)

Tuesday 23 August 2016

08:30 – 09:00 POSTER VIEWING (Boulevard foyer)

09:00 – 10:00 KEYNOTE PRESENTATION
Chair: Nick Holford

From transformative to disruptive - pharmacometrics' crucial role for inferring treatment effectiveness - #130 Prof Carl Peck, University of California San Francisco, USA

10:20 – 10:25 Morning tea (Boulevard foyer)

10:30 – 12:00 SYMPOSIUM 7
Influence of body composition and age on pharmacokinetics (Facilitated by Nick Holford and Yusuke Tanigawara)

10:30 – 10:35 Opening remarks

10:35 – 10:55 Using normal fat mass to account for body size and composition - #131 Nick Holford, University of Auckland, New Zealand

10:55 – 11:20 Prediction of fat free mass in adults and children - #132 Hesham Al-Sallami, University of Otago, New Zealand

11:20 – 11:45 The importance of body size for bridging studies - #133 Masato Kaneko, Bayer, Japan

11:45 – 12:00 A simple mechanistic pharmacometric model for HIV in children and adults - #134 Joe Standing, University College London, United Kingdom

12:00 – 13:25 Lunch (Boulevard foyer)

POSTER PRESENTATIONS (12:15 – 13:15)
7. Influence of body composition and age on pharmacokinetics
8. Pharmacometrics applications in non-communicable diseases
9. Other (abstracts #266 – #280)

13:30 – 15:00 SYMPOSIUM 8
Pharmacometrics applications in non-communicable diseases (Facilitated by Stephen Duffull)

13:30 – 13:35 Opening remarks

13:35 – 13:55 Using a PK/PD modeling approach to optimize the dosing regimen of secukinumab for the treatment of moderate to severe plaque psoriasis - #135 Michael Looby, Novartis, Switzerland

13:55 – 14:20 Population pharmacokinetics and pharmacodynamics of an oral glucagon receptor antagonist to optimize dosing in patients with type 2 diabetes mellitus - #136 Emmanuel Chigutsa, Eli Lilly, USA

14:20 – 14:45 Recommended doses of Levobupivacaine for TAP Blocks: Development of a pharmacokinetic model and estimation of the risk of symptoms of local anesthetic systemic toxicity - #137 Ignacio Cortinez, Pontificia Universidad Catolica de Chile, Chile

14:45 – 15:00 A Framework for quantifying the influence of adherence and dose individualization – #138 Piyanan Assawasuwannakit, University of Otago, New Zealand and Mahidol University, Thailand

15:00 – 15:30 CONFERENCE CLOSE